Browse Articles

Discover research articles across all indexed journals

Prognostic value of the pre-treatment systemic inflammation response index (SIRI) for progression-free survival in EGFR-mutant advanced lung adenocarcinoma.

Journal of Clinical Oncology Dang Huu Hai Tran, Xuan-Dung Ho, Thi Thuy Nguyen Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.292

292 Background: Although EGFR-tyrosine kinase inhibitors (TKIs) serve as the cornerstone of treatment for advanced lung adenocarcinoma with sensitizing mutations, predicting long-term therapeutic durability remains challenging. Given the established role of host systemic inflammation in driving malignancy progression and drug resistance, we investigated the baseline Systemic Inflammation Response Index (SIRI) as a potential tool for outcome prediction and risk stratification in these patients. Methods: This retrospective study analyzed 101 patients with EGFR-mutant advanced lung adenocarcinoma receiving first- through third-generation TKIs (January 2022 – December 2025). SIRI was determined using baseline absolute blood counts: (Neutrophils x Monocytes) / Lymphocytes. An optimal threshold was identified via ROC curve analysis. Progression-free survival (PFS) distributions were assessed using Kaplan-Meier estimates. A multivariate Cox proportional hazards model was employed to determine independent prognostic significance, adjusting for performance status, intracranial involvement, TKI type, and mutation patterns. Results: The optimal SIRI cutoff was 2.53 (AUC: 0.651). The cohort’s median PFS was 10.0 months. Patients in the low-SIRI group (≤ 2.53) achieved a significantly superior median PFS compared to those in the high-SIRI group (13.0 vs. 7.0 months; log-rank p = 0.002). Multivariate analysis confirmed that an elevated pre-treatment SIRI independently predicted shorter PFS (Hazard Ratio [HR]: 2.020; 95% CI: 1.251–3.260; p = 0.004). Notably, other clinical parameters, including ECOG status (p = 0.208) and TKI generation (p = 0.206), did not retain independent prognostic weight. Conclusions: Baseline SIRI is a robust, non-invasive, and easily accessible biomarker that independently predicts PFS in patients with advanced lung adenocarcinoma on EGFR-TKI therapy. Incorporating this index into routine clinical evaluation facilitates improved risk stratification and supports more personalized management strategies in the targeted therapy era. Survival outcomes and multivariate Cox regression analysis (n=101). Variable Median PFS (months) Log-rank (p) Adjusted HR (95% CI) p-value* SIRI Level* 0.002 0.004 ≤ 2.53 13.0 1.0 (Reference) > 2.53 7.0 2.020 (1.251–3.260) ECOG PS (0-1 vs. 2) 11.0 vs. 8.5 0.150 1.340 (0.850–2.120) 0.208 TKI Gen (1/2 vs. 3) 10.5 vs. 9.5 0.312 1.180 (0.760–1.840) 0.206 Brain Met (No vs. Yes) 12.0 vs. 9.0 0.084 1.450 (0.920–2.280) 0.115 *Abbreviations: HR, hazard ratio; CI, confidence interval; PFS, progression-free survival. p-value from Multivariate Cox Model. SIRI: (Neutrophils × Monocytes) / Lymphocytes.

A user-intent guided diffusion-segmentation collaborative framework for controllable digital media content generation

Scientific Reports Yantong Long, Sixi Chen Jul 01, 2026 DOI: 10.1038/s41598-026-57270-2

Validation and feasibility of symptom management toolkit among cancer survivors and caregivers in India.

Journal of Clinical Oncology Deepak Saini, Abhishek Shankar, Priyadharshini Mari et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.351

351 Background: Cancer survivors receiving treatment or on follow-up face substantial burden of managing their symptoms. Many cancer survivors experience fatigue, pain, nausea/vomit and other symptoms of mild to moderate grade for which they visit hospitals. This increased burden already overburden healthcare facilities. We developed a Symptom Management Toolkit (SMT) to be used by cancer survivors or caregivers to manage symptoms by themselves. This study evaluates the validity and feasibility of SMT among survivors of solid carcinoma. Methods: a validation study was conducted among cancer survivors with diagnosis of solid malignancy who were currently receiving treatment or are on follow up. Participants aged 18-65 years with Eastern Cooperative Oncology Group (ECOG) Performance Score of 2 or less were included in the study. The socio-demographic data was collected through a structured questionnaire which include education, residence, work, medical, family history, smoking, and alcohol history was taken. A 13 symptoms-based SMT was provided to manage the symptoms at home. The symptoms were graded and their management instructions were provided. The content validity was assessed through review by expert. The construct validity was evaluated through group comparison and symptoms correlations. Results: A total of 65 participants were included in this study with 58.5% females and 41.5% being male. 43.1% of participants reported history of tobacco use while alcohol intake was reported in only 29.2% participants. 27.7% patients have hypertension, 23.1% diabetes mellitus as comorbidity. 10.8% participants reported family history of cancer. The study inculded 27.7% breast cancer, 18.5% oral cancer, 16.9% gynaecological cancer, 10.8% lung cancer and 26.2% other solid cancer cases. 63.1% survivors were receiving chemotherapy including targeted therapy, 18.5% chemoradiotherapy, 10.8% radiation therapy and 7.7% was on follow-up. The most common symptoms reported were fatigue (63.1%), pain (56.9%), nausea or vomiting (44.6%), and dry mouth (40%). The content validity shows strong expert agreement with calculation of content validity indices (item-level CVI 0.85–1.00; scale-level CVI 0.92). The criterion validity showed agreement between SMT-based patient self-grading and clinician assessment (κ = 0.70). the feasibility of SMT was high among survivors. Around 86.2% of survivors and their caregivers were able to understand easily the instruction provided. The adherence to the SMT was also higher (73.4%). 64.6% of survivors reported improved symptom management through use of SMT. There were 13.8% decrease in hospital visit after SMT use (24/65 vs 15/65 visit before and during SMT use). Conclusions: The feasibility and high acceptability of SMT can improve symptom management and reduce hospital visits. The SMT can be used as self-management tool to reduce the unscheduled visits to the hospitals.

Serum laminin γ2 monomer (LG2m) to reflect a CD90-driven immunosuppressive niche and survival benefit from atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal of Clinical Oncology Kouki Nio, Tetsuro Shimakami, Hajime Takatori et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.310

310 Background: Atezolizumab plus bevacizumab (A+B) improves survival compared with sorafenib (Sora) in advanced hepatocellular carcinoma (HCC), yet predictive biomarkers remain undefined. Laminin γ2 monomer (LG2m) is expressed in CD90-positive stem-like HCC cells. We investigated whether LG2m reflects an immunosuppressive tumor microenvironment (TME) and modifies survival benefit from A+B. Methods: Single-cell spatial analysis (PhenoCycler) was performed in resected HCC specimens to characterize CD90-positive tumor cells and immune cell distribution according to LG2m expression. In advanced HCC (n=135; A+B n=85, Sora n=50), serum LG2m was measured using chemiluminescent immunoassay. A cutoff of 49.3 pg/mL was applied. Progression-free survival (PFS) and overall survival (OS) were analyzed. Results: Spatial analysis revealed that LG2m-high tumors showed dense accumulation of CD90-positive cells at the tumor boundary, enrichment of CD206-positive macrophages, and reduced infiltration of activated CD4⁺ and CD8⁺ T cells, consistent with an immunosuppressive niche. In the overall cohort, A+B significantly improved PFS (HR 0.45; P<0.001) and OS (HR 0.50; P=0.003) compared with Sora. However, stratified analysis demonstrated effect modification by LG2m. In LG2m-low patients, A+B markedly improved PFS (HR 0.33; P<0.001) and OS (HR 0.27; P<0.001). In contrast, in LG2m-high patients, A+B did not show superiority over Sora for either PFS (HR 0.65; P=0.15) or OS (HR 0.78; P=0.48). Conclusions: LG2m identifies an immunosuppressive, CD90-driven TME and delineates a subgroup of HCC patients in whom survival benefit from A+B is attenuated. Serum LG2m may serve as a clinically actionable biomarker to refine immunotherapy selection in advanced HCC.

Inside Front Cover: Specific Ion Effects of Chaotropic and Superchaotropic Anions Probed by Raman Hydration‐Shell Spectroscopy (Angew. Chem. Int. Ed. 27/2026)

Angewandte Chemie International Edition Werner M. Nau, Denilson Mendes de Oliveira, Andres S. Urbina et al. Jul 01, 2026 DOI: 10.1002/anie.2026-m0506073000

Modeling irrigation strategy impacts on conjunctive surface–groundwater use in the semi-arid Sarab Basin, Iran

Scientific Reports Alireza B. Dariane, Mahsa Ghasemzadeh, Mehran Ghodrati Jul 01, 2026 DOI: 10.1038/s41598-026-59865-1

Abstract Water scarcity in the semi-arid Sarab Basin, exacerbated by population growth and inefficient irrigation, demands integrated water management. This study aims to apply a novel WEAP-HYDRUS-MODFLOW-MT3DMS framework linking all hydrological compartments to assess the quantity and quality impacts of irrigation modernization and management strategies in Urmia Lake Basin, Iran. Simulations for 2009–2018 evaluated sprinkler, 60% (S60) and 70% (S70) efficiency, and drip systems, 80% (D80) and 90% (D90) efficiency under two strategies: water conservation via demand management strategy (DMS) and agricultural development strategy (ADS) using saved water. Results show irrigation modernization (S60 to D90) under DMS increases streamflow from 84.3 mcm/yr to 112–131 mcm/yr, while groundwater levels rise by 1.5–2.4 m with TDS increasing by 1.3–2 mg/L. Conversely, ADS reduces streamflow to 74.5–79.8 mcm/yr, lowers groundwater levels by 0.6–1.2 m, and raises TDS by 0.9–1.9 mg/L. Surface water quality, with groundwater return flow considered, improves by 94–136 mg/L (DMS) and 25–100 mg/L (ADS). The study underscores irrigation modernization advantages under DMS while warning against reallocation in ADS. Findings emphasize policymakers should prioritize water constraints over land expansion for sustainable development in semi-arid regions like Iran, as irrigation modernization alone cannot restore Urmia Lake.

Macrophages Intracellularly Gelated With Bioactive Hydrogels for Synergistic Neutralization, Eradication, and Osteopromotion in Periodontitis Treatment

Advanced Materials Mingyi Liu, Yunfan Cai, Yan Wang et al. Jul 01, 2026 DOI: 10.1002/adma.202519288

ABSTRACT Conventional periodontitis therapy is limited by the lack of an all‐in‐one material with the desired functions of toxin neutralization, pathogen eradication, and osteopromotion. Exploiting the innate capacity of macrophages to recognize and neutralize pathological stimuli, this study develops novel engineered macrophage‐based materials: phytate/Zn 2 + ‐loaded gelated macrophages (PZ‐GMs). These materials are fabricated at room temperature by polymerizing polycationic hydrogels and loading phytate/Zn 2 + into live macrophages, innovatively integrating the natural immune neutralization function of intact macrophage membranes with the bioactivity of intracellular hydrogels. PZ‐GMs are found to eradicate >99.99% of pathogens, remove >90% of bacterial toxins, and eliminate >80% of related inflammatory factors, while simultaneously promoting bone repair through in situ mineralization and osteoinduction. They can be further incorporated into a hydrogel designed for acid‐triggered release, ensuring targeted delivery to inflamed sites. In a murine periodontitis model, PZ‐GMs facilitate periodontal regeneration via a dual mechanism: transforming the pathological microenvironment induced by bacteria and toxins and fostering the remodeling of an osteogenic microenvironment. Furthermore, oral microbiome homeostasis is restored. Collectively, PZ‐GMs represent a promising all‐in‐one neutralization–eradication–osteopromotion material for highly efficient periodontitis therapy.

Anisamide-conjugated PLGA nanoparticles for targeted co-delivery of sorafenib and paclitaxel in colorectal cancer.

Journal of Clinical Oncology Madhunika Agrawal, Nihal Kumar, Vivek Yadav et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.85

85 Background: Colorectal cancer continues to be one of the leading cancers, ranking third in occurrence and second in cancer-associated fatalities worldwide. Additionally, its therapy is limited by drug solubility, systemic toxicity and resistance. The high rates of incidence, death and treatment challenges emphasize the critical need, for improved therapeutic approaches. Sorafenib (SOR), a multi-targeted kinase inhibitor inducing apoptosis and ferroptosis, and paclitaxel (PTX), a microtubule-stabilizing agent, are mechanistically complementary but limited by poor bioavailability. Sigma-1 receptor (σ1R), overexpressed on CRC cells, offers a targetable entry point via anisamide (AA), a benzamide ligand. This study developed AA-conjugated PLGA nanoparticles co-loaded with SOR and PTX as targeted CRC nanotherapy. Methods: AA was conjugated to Pluronic F-127 via DCC condensation, confirmed by FTIR and ¹H NMR. SOR+PTX AA-PLGA NPs were fabricated by nanoprecipitation and optimized using Box-Behnken Design. The formulation was optimized and assessed for characteristics in-vitro uptake, cytotoxic effects, and apoptosis in HCT116, HT29, and CT26 cells. In vivo antitumor efficacy, pharmacokinetics, hemocompatibility, and organ toxicity were assessed. Results: After optimization, the SOR+PTX-AA-PLGA nanoparticles displayed a size of 192.21±7.55 nm, a PDI of 0.252±0.065, and drug loading (%) of 8.87±1.03 (SOR) and 8.43±1.44 (PTX). The drugs were released slowly in two phases and followed Korsmeyer-Peppas law of drug release. Targeted nanoparticles exhibited 2.0-2.7 fold higher cytotoxic activity compared to free drug combinations. Significant decreases in IC 50 value were evidenced in all the three colorectal cancer cell lines with HT29 at 1.81 µg/mL, HCT116 at 1.41 µg/mL, and CT26 at 1.62 µg/mL. The apoptotic index radically increased up to 1.44 (HT29), 1.28 (HCT116), and 1.38 (CT26), the maximum values, in all the groups. In vivo SOR+PTX AA, PLGA nanoparticles resulted in a tumor size of 6.51 fold smaller than the control and was even more effective than free SOR (1.22 fold) and PTX (1.50 fold). Pharmacokinetic analysis demonstrated that the AUC was increased by 2.31 times, and the half life was extended by 4.5 times compared to free drugs, pointing to greater drug persistence in the body. At the same time, no alterations were detected in the liver/kidney function markers (ALT, AST, BUN, creatinine; P>0.05) of the treated groups, and only trace levels of hemolysis were observed, which are indications of safety. Conclusions: Anisamide targeted PLGA nanoparticles markedly enhanced co, delivery, cellular uptake, cytotoxicity, and apoptosis, which were reflected in better tumor suppression and longer systemic exposure. This delivery system has great potential for targeted colorectal cancer therapy.

Beyond PSA and PSMA: Defining PSA–PSMA discordance for FDG PET and genomic stratification in mCRPC.

Journal of Clinical Oncology Teenu Kamboj, Shubhkaran Singh Gill Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.194

194 Background: PSA kinetics and PSMA PET guide mCRPC response, yet PSA–PSMA discordance occurs in ~20–30% of patients. We hypothesized discordance reflects TP53/RB1-driven lineage plasticity with a PSMA-low, FDG-high phenotype. This study links discordance to survival and lineage-plastic genomic alterations. Methods: This prespecified retrospective biomarker analysis testing the hypothesis that PSA–PSMA discordance independently predicts worse OS and PFS versus concordant response. The null hypothesis assumed no hazard difference. We analyzed 1,850 mCRPC patients treated with ARPIs, taxanes, or 177Lu-PSMA-617. Eligibility required serum testosterone <50 ng/dL, prior ARPI or taxane, ECOG 0-2 and paired baseline and 8–12 week PSMA PET with PSA; patients without paired data were excluded. Discordance was defined as ≥50% PSA decline with RECIP 1.0 progression at 8-12 weeks confirmed by central review. Outcomes were correlated with ^18F-FDG PET/CT and TP53, RB1, PTEN alterations from tissue or cfDNA (n= 1,120). Models adjusted for LDH, ALP, visceral metastasis. Primary endpoints were OS and PFS. Powered for overall survival, assuming 20% discordance and median OS 16 months, 1,800 patients provided >90% power to detect HR 1.5 at two-sided α 0.05 with type I error 5% and type II error 10%. Survival analyses used the intention-to-treat population using Kaplan–Meier and adjusted Cox models. Genomic analyses included patients with tissue or cfDNA profiling (collected at progression or within 30 days of PSMA PET) using validated ≥300-gene NGS panels in CLIA laboratories before subsequent therapy. PSMA PET used 68Ga-PSMA-11 or 18F-DCFPyL and 18F-FDG PET used standard 60 ± 10 minute acquisition. Progression was defined per RECIP 1.0. Genomic enrichment used logistic regression. Discordance and genomic alterations were modeled as binary variables with hierarchical testing, OS first. Results: Median follow-up was 14.6 months. Discordance occurred in 20.4% (n=377), 82% from PSA decline with radiographic progression. Discordant patients had worse OS (7.2 vs 16.4 months; aHR 2.45; 95% CI 1.8–3.3; p<0.001) and PFS (3.8 vs 8.4 months; HR 2.10; 95% CI 1.6–2.8; p<0.0001). 85% were FDG-avid. TP53/RB1/PTEN alterations were enriched 3.5-fold (48% vs. 14%; p < 0.001). Findings were consistent across ARPIs (HR 2.3), taxanes (HR 2.1), and ^177Lu-PSMA-617 (HR 2.5). Features aligned with treatment-emergent small cell or AR-indifferent biology. 42% met criteria for platinum intensification. Conclusions: PSA–PSMA discordance is a clinically actionable marker of lineage plasticity and TP53/RB1-deficient mCRPC. These data support integrating 18F-FDG PET and genomic profiling to guide therapy beyond AR or PSMA targeting.

An in-vivo evaluation of the multi-channel bioimpedance method in monitoring radiofrequency ablation lesions

Scientific Reports X. Liu, N. A. Huyen, B. Tony et al. Jul 01, 2026 DOI: 10.1038/s41598-026-58607-7

Electron‐Enriched Ru Nanoclusters Mediating Surface Reconstruction of Phosphide Catalysts for Efficient Water Electrolysis

Advanced Materials Xi‐Wen Chang, Lebin Cai, Jia‐Yang Luo et al. Jul 01, 2026 DOI: 10.1002/adma.73792

ABSTRACT Transition metal phosphides (TMPs) are attractive bifunctional electrocatalysts for alkaline water electrolysis. However, their practical deployment is hindered by a fundamental reconstruction paradox. Electron‐rich metal–phosphorus frameworks are intrinsically favorable for the hydrogen evolution reaction (HER), whereas efficient oxygen evolution reaction (OER) requires rapid in situ conversion into high‐valence metal (oxy)hydroxides—a transformation that is typically kinetically sluggish in conventional TMPs. Here, we report a dynamic pre‐catalyst architecture in which electron‐enriched Ru nanoclusters are anchored at the interfaces of bimetallic FeCo phosphides (Ru–FeCoP@NF). The Ru nanoclusters act as localized, potential‐responsive electron reservoirs, extracting and redistributing electrons from adjacent Fe/Co sites via interfacial charge‐transfer pathways. This interfacial electron‐pump effect selectively destabilizes the metal–phosphorus framework, markedly reducing the kinetic barrier for OH − ‐induced surface reconstruction and enabling the early emergence of catalytically active FeCo (oxy)hydroxide species. Consequently, the catalyst maintains an electron‐rich metallic state conducive to HER while simultaneously accelerating dynamic surface evolution for OER. When integrated into an anion exchange membrane water electrolyzer, Ru–FeCoP@NF achieves 1.0 A cm − 2 at 1.77 V for 300 h in 1.0 M KOH at 80°C, delivering industrially relevant efficiency and operational durability.

Droplet Electricity Generators With Maximized Energy Collection Zone Enabled by Aloe‐Inspired Midrib and Cuticle

Advanced Materials Gibeom Lee, Eunbyeol Kim, Kyongtae Choi et al. Jul 01, 2026 DOI: 10.1002/adma.202523637

ABSTRACT Leveraging water as an abundant and continuously available natural resource, droplet electricity generators (DEGs) have gained significant attention for their ability to produce high instantaneous voltages from the simple impact of water droplets. However, conventional DEGs are fundamentally limited by their narrow energy collection zones, confined to regions immediately adjacent to the switch electrode. In nature, Aloe vera overcomes a similar spatial challenge by guiding scarce rainfall toward the root through its midrib‐like longitudinal ridge and water‐repellent wax‐rich cuticle—an integrated water‐guiding architecture that transports droplets over long distances with minimal loss. Here, inspired by this mechanism, we introduce a scalable DEG that maximizes the energy collection zone through an artificial droplet‐channeling strategy. A midrib‐inspired curvilinear geometry induces uni‐directional spreading upon impact, while an artificial hydrophobic cuticle composed of a hydrocarbon‐based OTS–squalane layer enables smooth, low‐retention sliding and robust interfacial stability. These features substantially expand the effective collection zone and yield approximately 236% higher charge output than a conventional DEG, unlocking new opportunities for large‐area, distributed, and environmentally adaptive droplet‐energy harvesting.

From neuroscience to oncology: Multi-agent AI replicating neural reasoning architecture for evidence-based colon cancer clinical decisions.

Journal of Clinical Oncology Noemi Noemi Perez Paz, Brad McDanel, Philip Perez Marjon et al. Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.17

17 Background: Colorectal cancer management requires integration of complex genomic data, clinical guidelines, and patient-specific factors. Current clinical decision support systems often lack transparency and fail to ensure guideline adherence. We developed GenomAI, a multi-agent AI reasoning system that replicates prefrontal cortex decision-making to provide verifiable, guideline-based treatment recommendations. The platform uses a hybrid Cache-Augmented Generation and Retrieval-Augmented Generation architecture. Methods: GenomAI employs specialized multi-modal AI agents for diagnosis, biomarker analysis, treatment planning, and clinical trial matching. The system integrates NCCN guidelines with patient genetic profiles, pathology reports, clinical data, and imaging through HL7/FHIR-compliant APIs or document upload. We validated GenomAI using 100 retrospective colorectal cancer cases, evaluating: (1) accuracy of NCCN guideline identification and application, (2) appropriateness of clarifying questions when clinical information was incomplete, (3) concordance with multidisciplinary tumor board decisions, and (4) transparency through complete audit trails with exact NCCN page references. Performance was compared against direct-answer AI models. Results: GenomAI achieved 100% accuracy in identifying relevant NCCN guideline sections and 99% concordance with tumor board decisions. The system appropriately requested follow-up data in 14 cases with insufficient information. Compared to Claude Opus 4.5 and GPT-5.2 (85%), Gemini 3 Pro (82%), and MedGemma 1.5 (62%), GenomAI demonstrated superior performance. The platform integrated comprehensive clinical data: laboratory values, molecular profiling (KRAS, NRAS, BRAF, MSI, TMB), pathology, imaging, and colonoscopy while incorporating patient-specific factors including toxicity risks, comorbidities, and age. All oncologist-validated recommendations included NCCN page references and confidence scores. GenomAI reduced evidence synthesis time by 40% versus manual review and successfully identified eligible clinical trials. Conclusions: GenomAI demonstrates high accuracy in providing NCCN guideline-compliant colorectal cancer treatment recommendations. The multi-agent architecture ensures transparency, appropriate clarification-seeking, and refusal when guidelines are not applicable. This validation establishes GenomAI as a promising clinical decision support tool enhancing physician workflow while maintaining guideline fidelity and patient safety. Future work will expand to additional cancer types and prospective evaluation.

Disproportionality analysis of musculoskeletal and connective tissue disorders associated with aromatase inhibitors: A real-world pharmacovigilance study.

Journal of Clinical Oncology Jeong-Hwa Yoon, Hyo Jung Kim, Yeon Hee Park Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.51

51 Background: Aromatase inhibitors (AIs) are a cornerstone of endocrine therapy for hormone receptor-positive breast cancer and are well known to induce musculoskeletal symptoms under profound estrogen deprivation. Although arthralgia and bone pain are well recognized, the broader spectrum of musculoskeletal adverse events has not been systematically evaluated in large scale pharmacovigilance data. Methods: We analyzed the U.S. FDA Adverse Event Reporting System database from 2004 to 2023, restricted to reports with a breast cancer indication to minimize confounding by off-label use. Analyses were performed within the MedDRA System Organ Class (SOC) “Musculoskeletal and connective tissue disorders”. The dataset comprised 549,824 adverse event reports corresponding to 154,633 unique cases, including 7,028 AI-exposed cases. Case/non-case disproportionality analyses were conducted at both the SOC and the Preferred Term (PT) levels within this SOC. Reporting odds ratios (RORs) and 95% confidence intervals (CIs) were calculated. A signal was defined as three or more AI exposed cases with a lower bound of the 95% CI of the ROR exceeding 1. Significant PTs were ranked by AI exposed case counts, and the top 10 were presented. Results: At the SOC level, 1,742 AI exposed cases were identified, showed significant disproportionality (ROR 1.82, 95% CI 1.72-1.92) (Table). At the PT level, 55 musculoskeletal PTs met the predefined signal criteria, with the top 10 presented in the Table. Among established musculoskeletal toxicities, “Arthralgia” was the most frequently reported PT (n=725; ROR 4.46, 95% CI 4.10-4.84), followed by “Bone pain”, “Pain in extremity”, “Myalgia”, and “Back pain”. Additional significant signals broadening the musculoskeletal spectrum included “Musculoskeletal stiffness”, “Musculoskeletal pain”, “Arthritis”, and “Trigger finger”. Conclusions: In this large post-marketing real-world pharmacovigilance analysis of reports with a breast cancer indication, AIs demonstrated significant and clinically relevant disproportionality across a broad spectrum of musculoskeletal adverse events. These findings support proactive musculoskeletal monitoring in AI treated patients and warrant further investigation. Disproportionality analysis results for AI-related adverse drug reactions. Terms AI cases reporting term ROR AI/ all other cases (95% CI) SOC Musculoskeletal and Connective Tissue Disorders 1742 1.82 (1.72, 1.92) PTs Arthralgia 725 4.46 (4.1, 4.84) Bone Pain 297 3.29 (2.91, 3.73) Pain In Extremity 262 2.21 (1.94, 2.52) Myalgia 248 3.12 (2.73, 3.58) Back Pain 171 1.59 (1.36, 1.86) Musculoskeletal Stiffness 98 4.93 (3.95, 6.15) Musculoskeletal Pain 84 2.84 (2.26, 3.57) Muscle Spasms 78 1.55 (1.23, 1.95) Trigger Finger 78 10.82 (8.23, 14.22) Arthritis 74 2.77 (2.17, 3.54)

Unlocking Surface Sodiation Threshold of Titanium Dioxide via Coupled Electrochemical‐Thermal Activation

Angewandte Chemie International Edition Dafu Tang, Sicheng Fan, Chao Li et al. Jul 01, 2026 DOI: 10.1002/anie.4368463

ABSTRACT Titanium dioxide anodes for sodium‐ion batteries undergo an electrochemically‐induced phase transformation from crystalline to active amorphous phase in a thin surface layer, resulting in surface‐dependent capacities. The origins of this limited active layer remain unclear. Herein, we reveal that the sluggish movement of the amorphous|crystalline boundary during initial sodiation determines the thickness of the surface‐active layer. To unlock surface sodiation threshold, we propose a coupled electrochemical‐thermal activation protocol to promote the continuous movement of the amorphous|crystalline boundary during the initial cycle, thereby permanently increasing the reversible sodiation capacity. The anatase TiO 2 ‐35 nm anode delivers an enhanced capacity from 116 to 190 mAh g −1 at 0.1 A g −1 after electrochemical‐thermal activation, accompanied by its high‐rate capability and long‐term cyclability. The electrochemical‐thermal activation is also efficient for enhancing the Li + /Na + storage capacities of rutile TiO 2 anodes. This work opens a pathway for enhancing electrochemically‐induced irreversible phase transformations with enhanced charge storage performance.

MSCSM-YOLOv11s: multi-scale feature extraction and CSM attention for small target detection

Scientific Reports Shuting Huang, Juan Guo Jul 01, 2026 DOI: 10.1038/s41598-026-58999-6

Nonlocal Metaspire: A Scalable Elastic Material Platform With Decoupled Mechanical Modes

Advanced Materials Seung Han Kim, Myung Hwan Bae, Ye Jeong Shin et al. Jul 01, 2026 DOI: 10.1002/adma.73822

ABSTRACT Nonlocal metamaterials, which are metamaterials that interact with non‐neighboring unit cells, have recently attracted growing attention as a new paradigm for wave control owing to their extraordinary band structures. However, existing nonlocal metamaterials remain limited in scalability, making it difficult to implement multiple nonlocal couplings and higher‐dimensional arrays. Elastic nonlocal metamaterials have an additional limitation of mode coupling, which hinders clear investigations of unique nonlocal wave phenomena in individual elastic wave modes. This study addresses these limitations by proposing a new material platform for elastic nonlocal metamaterials, leveraging the “Metaspire” architecture with sequential rotation. Subsequently, the detailed wave motions around the maxon and roton are investigated, and the role of nonsymmorphic symmetry in flexural band behavior is further examined. In addition, actual fabrication and experimental validation are conducted to further support the proposed approach. The results quantitatively demonstrate the high scalability of the proposed method and its suppression of mode coupling. The proposed material platform provides a basis for the development of multifunctional wave platforms, thereby enabling various new‐wave systems and devices.

Flux-coupled network pharmacology to identify AR–HIF1A–mTOR tri-axis as a mechanistic vulnerability in genitourinary (GU) cancers.

Journal of Clinical Oncology Lutfat Abimbola Usman Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.8

8 Background: Advanced genitourinary cancers are driven by intertwined androgen receptor (AR) signaling, HIF-1α-mediated hypoxia adaptation, and extensive metabolic rewiring, with mTOR serving as a critical convergence node. These pathways exhibit profound bidirectional crosstalk; AR fuels glycolysis and lipogenesis, hypoxia modulates AR activity while enforcing Warburg metabolism, and sustained mTORC1 signaling amplifies anabolic programs and therapy resistance, yet their integrated regulatory and metabolic dynamics have not been systematically modeled at the genome scale. Methods: Metabolic fluxes were inferred using Recon3D-based FBA; AR/HIF-1α/mTOR regulatory circuitry was reconstructed via dynamic Bayesian inference and integrated with crosstalk dynamics using logic-based differential equations (LogicODEs). Candidate repurposing compounds were identified and ranked by integrated 3D pharmacophore screening, high-throughput molecular docking, and all-atom molecular dynamics refinement in explicit solvent. Results: Flux simulations showed GU tumors shift toward fatty acid oxidation + glutamine fueling to sustain ATP under hypoxia. HIF1A activation tightened feedback on glycolytic enzymes, while AR amplified lipid biosynthesis genes (SCD1, ACACA). Network logic modeling revealed AR–HIF1A–mTOR as a tightly interdependent tri-axis where disrupting one destabilizes others. Computational drug screening identified ursolic acid and baicalein as multi-axis disruptors binding AR-LBD, HIF1A-PAS, and mTOR active sites. MD predicted stable tri-target occupation. Conclusions: Mechanistic-computational modeling identifies the AR–HIF1A–mTOR tri-axis as a vulnerable system in GU cancers. Multi-target natural compounds can collapse this regulatory architecture.

Comparative efficacy and safety of first-line systemic combinations for advanced urothelial carcinoma: A Bayesian network meta-analysis.

Journal of Clinical Oncology Rahul Falodia, Shankar Biswas, Yashasvi Srivastava Jul 01, 2026 DOI: 10.1200/jco.2026.44.19_suppl.184

184 Background: The phase 3 EV-302 trial established enfortumab vedotin plus pembrolizumab (EV+P) as the new first-line (1L) standard of care over platinum-based chemotherapy (PBCT) for advanced urothelial carcinoma (aUC). However, comparative efficacy and toxicity between EV+P and the broader landscape of modern frontline regimens including chemo-immunotherapy (IO), dual IO, and maintenance strategies remain unestablished. We conducted a Bayesian network meta-analysis (NMA) to resolve these comparative efficacy and safety profiles. Methods: A systematic literature search identified phase 3 randomized controlled trials evaluating 1L systemic therapies for aUC. Interventions included EV+P, IO+PBCT (nivolumab, atezolizumab, pembrolizumab), dual IO (durvalumab+tremelimumab), maintenance IO (avelumab), and targeted combinations (pembrolizumab+lenvatinib). Endpoints included OS, PFS, and Grade 3 treatment-related adverse events (TRAEs). A Bayesian NMA with a random-effects model was conducted utilizing JAGS. Efficacy was evaluated via Hazard Ratios (HR), safety via Odds Ratios (OR), and treatment rankings via the Surface Under the Cumulative Ranking curve (SUCRA). Results: Seven pivotal trials comprising >5,500 patients were included. For OS, EV+P demonstrated significant superiority over PBCT (HR 0.47, 95% Credible Interval [CrI] 0.38-0.58) and ranked most efficacious (SUCRA 99%). Sequential PBCT followed by avelumab maintenance ranked second for OS (HR 0.69; SUCRA 78%), followed by nivolumab+PBCT (HR 0.78; SUCRA 62%). For PFS, EV+P similarly achieved the highest ranking (HR 0.45, 95% CrI 0.38-0.54; SUCRA 98%), followed by avelumab maintenance (HR 0.62). Safety profiles exhibited stark heterogeneity. Analysis of Grade 3 TRAEs revealed that dual IO (durvalumab+tremelimumab) ranked as the safest regimen (27.0% Grade 3 TRAEs; OR vs PBCT < 1). EV+P demonstrated a favorable safety profile compared to chemotherapy alone (55.9% vs 69.5%; OR < 1). Conversely, all concurrent IO+PBCT triplets resulted in increased toxicity compared to PBCT alone (OR > 1), with Grade 3 TRAEs ranging from 61.8% to 81.0%. Conclusions: EV+P provides unprecedented OS and PFS benefits, firmly ranking as the most efficacious 1L strategy for aUC while demonstrating a manageable Grade 3 toxicity profile relative to traditional chemotherapy. Notably, concurrent chemo-immunotherapy triplets offer inferior survival benefits and higher toxicity burdens. The distinct safety profiles highlight a critical need for biomarker-driven patient selection and optimized post-progression sequencing.

A phase-equilibrium outranking method with hysteresis-banded thresholds for robust multi-criteria decision making: PEOM

Scientific Reports Mehmet Akif Yerlikaya, Yunus Sayan, Murat Binici et al. Jul 01, 2026 DOI: 10.1038/s41598-026-59606-4